My watch list
my.bionity.com  
Login  

Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer

01-Mar-2019

Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough. As a result of the trial initiation, Evotec received a payment of € 3 m.

In October 2012, Evotec and Bayer began their multi-target discovery alliance with the shared goal to discover three clinical candidates with a focus in the field of endometriosis. The successful and productive long-term alliance ended in 2018, generating six first-in-class pre-clinical candidates three of which have progressed into Phase I clinical trials. Bayer advanced a first programme into a Phase II trial in chronic cough in July 2018 and has now initiated a further candidate into a second Phase II trial for the same indication.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “Our long-term alliance with Bayer represents our continued commitment to bring new therapeutics options to millions of patients. We are pleased to see a second compound from this alliance moving into Phase II studies for chronic cough, a debilitating condition affecting about ten percent of the global population and with no approved, curative therapy.”

Facts, background information, dossiers
More about Evotec
  • News

    Evotec and Celmatix enter into strategic collaboration

    Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometr ... more

    Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian

    Evotec SE announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc. Aeovian and Evotec entered into a drug discovery partnership in 2017 to discover and develop new and highly selective ... more

    Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration

    Evotec SE and Indivumed GmbH announced that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer. Under the terms of the collaboration agreement, Evotec received full access to the colorect ... more

  • Companies

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

    Evotec SE

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

More about Bayer
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE